Oxybutynin Chloride Syrup Rx
Generic Name and Formulations:
Oxybutynin chloride 5mg/5mL.
Various generic manufacturers
Indications for Oxybutynin Chloride Syrup:
Symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (eg, urinary urgency, frequency, leakage, urge incontinence, dysuria).
5mg 2–3 times a day; max 20mg/day.
<5yrs: not recommended. ≥5yrs: 5mg twice daily; max 15mg/day.
Uncontrolled glaucoma. GI obstruction. Paralytic ileus. Intestinal atony in elderly or debilitated. Severe colitis. Myasthenia gravis. Megacolon. Toxic megacolon in ulcerative colitis. Obstructive uropathies. Unstable cardiovascular status in acute hemorrhage.
Activities requiring mental alertness. Diarrhea. Hepatic or renal disease. Autonomic neuropathy. Hyperthyroidism. Cardiovascular disease. Hiatal hernia. GI or GU obstruction. Ulcerative colitis. Exposure to extreme heat. Elderly. Pregnancy (Cat.B). Nursing mothers.
Potentiates drowsiness with alcohol, other CNS depressants. Additive anticholinergic effects with other anticholinergics. May be potentiated by CYP3A4 inhibitors. Decreases GI motility, possibly affecting absorption of other drugs.
Dry mouth, constipation, somnolence, headache, diarrhea, nausea, tachycardia, blurred vision, dry eyes, other anticholinergic effects.
Formerly known under the brand name Ditropan.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|